Literature DB >> 23398519

Health-related quality of life, optimism, and coping strategies in persons suffering from localized scleroderma.

B Szramka-Pawlak1, A Dańczak-Pazdrowska, T Rzepa, A Szewczyk, A Sadowska-Przytocka, R Żaba.   

Abstract

The clinical course of localized scleroderma may consist of bodily deformations, and bodily functions may also be affected. Additionally, the secondary lesions, such as discoloration, contractures, and atrophy, are unlikely to regress. The aforementioned symptoms and functional disturbances may decrease one's quality of life (QoL). Although much has been mentioned in the medical literature regarding QoL in persons suffering from dermatologic diseases, no data specifically describing patients with localized scleroderma exist. The aim of the study was to explore QoL in localized scleroderma patients and to examine their coping strategies in regard to optimism and QoL. The study included 41 patients with localized scleroderma. QoL was evaluated using the SKINDEX questionnaire, and levels of dispositional optimism were assessed using the Life Orientation Test-Revised. In addition, individual coping strategy was determined using the Mini-MAC scale and physical condition was assessed using the Localized Scleroderma Severity Index. The mean QoL score amounted to 51.10 points, with mean scores for individual components as follows: symptoms = 13.49 points, emotions = 21.29 points, and functioning = 16.32 points. A relationship was detected between QoL and the level of dispositional optimism as well as with coping strategies known as anxious preoccupation and helplessness-hopelessness. Higher levels of optimism predicted a higher general QoL. In turn, greater intensity of anxious preoccupied and helpless-hopeless behaviors predicted a lower QoL. Based on these results, it may be stated that localized scleroderma patients have a relatively high QoL, which is accompanied by optimism as well as a lower frequency of behaviors typical of emotion-focused coping strategies.

Entities:  

Mesh:

Year:  2013        PMID: 23398519     DOI: 10.1080/13548506.2013.764461

Source DB:  PubMed          Journal:  Psychol Health Med        ISSN: 1354-8506            Impact factor:   2.423


  7 in total

1.  Association between quality of life and clinical characteristics in patients with morphea.

Authors:  G Bali; S Kárpáti; M Sárdy; V Brodszky; B Hidvégi; F Rencz
Journal:  Qual Life Res       Date:  2018-06-19       Impact factor: 4.147

2.  Health-related quality of life in morphoea.

Authors:  N K Klimas; A D Shedd; I H Bernstein; H Jacobe
Journal:  Br J Dermatol       Date:  2015-04-08       Impact factor: 9.302

3.  Quality of Life and Optimism in Patients with Morphea.

Authors:  Beata Szramka-Pawlak; Aleksandra Dańczak-Pazdrowska; Teresa Rzepa; Aleksandra Szewczyk; Anna Sadowska-Przytocka; Ryszard Zaba
Journal:  Appl Res Qual Life       Date:  2013-11-10

4.  Associations between Disease Activity/Severity and Damage and Health-Related Quality of Life in Adult Patients with Localized Scleroderma-A Comparison of LoSCAT and Visual Analogue Scales.

Authors:  Anna Lis-Święty; Alina Skrzypek-Salamon; Irmina Ranosz-Janicka; Ligia Brzezińska-Wcisło
Journal:  J Clin Med       Date:  2020-03-11       Impact factor: 4.241

Review 5.  Quality of Life in Patients with Morphea: A Cross-Sectional Study and a Review of the Current Literature.

Authors:  Justyna Szczęch; Dominik Samotij; Kamila Jaworecka; Aleksandra Tobiasz; Adam Reich
Journal:  Biomed Res Int       Date:  2020-03-13       Impact factor: 3.411

6.  A novel patient-reported outcome for paediatric localized scleroderma: a qualitative assessment of content validity.

Authors:  C K Zigler; K Ardalan; S Lane; K L Schollaert; K S Torok
Journal:  Br J Dermatol       Date:  2019-10-23       Impact factor: 9.302

7.  Health-related quality of life and its influencing factors in adult patients with localized scleroderma - a cross-sectional study.

Authors:  Anna Lis-Święty; Alina Skrzypek-Salamon; Irmina Ranosz-Janicka; Ligia Brzezińska-Wcisło
Journal:  Health Qual Life Outcomes       Date:  2020-05-12       Impact factor: 3.186

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.